Answers are grounded in this paper and cite their sources.
Atherothrombotic vascular disease is the leading cause of death in much of the Western world. Therapeutic lifestyle modification, risk factor control and statin-mediated low-density lipoprotein cholesterol (LDL-C)-lowering have been shown to significantly reduce atherothrombotic cardiovascular events. However, nearly two-thirds of adverse cardiovascular events continue to occur despite current interventions. In view of the known epidemiological data showing an inverse relationship between coronary heart disease and high-density lipoprotein-cholesterol (HDL-C), and coupled with experimental observations and proof-of-concept early clinical trials, the focus is now shifting to HDL as a therapeutic strategy for further cardiovascular risk reduction. Direct infusion of recombinant HDL/apolipoprotein A-I is one such promising approach that is reviewed in this paper.
No takes yet. Share an insight, caveat, or question.
Anil Shah (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: